pemetrexed + topotecan
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer
Trial Timeline
Mar 1, 2006 → Jan 1, 2009
NCT ID
NCT00315861About pemetrexed + topotecan
pemetrexed + topotecan is a phase 1 stage product being developed by Eli Lilly for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00315861. Target conditions include Ovarian Cancer, Endometrial Cancer, Cervical Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00315861 | Phase 1 | Completed |
Competing Products
20 competing products in Ovarian Cancer